A double-blind, placebo-controlled, balanced, 4-way, incomplete block design to evaluate the effects of a single administration of SAM-531 on sleep electroencephalogram (EEG) and quantitative wake EEG (qEEG) in healthy subjects

Trial Profile

A double-blind, placebo-controlled, balanced, 4-way, incomplete block design to evaluate the effects of a single administration of SAM-531 on sleep electroencephalogram (EEG) and quantitative wake EEG (qEEG) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2010

At a glance

  • Drugs Cerlapirdine; Donepezil
  • Indications Alzheimer's disease
  • Focus Pharmacodynamics
  • Sponsors Wyeth
  • Most Recent Events

    • 13 Jul 2010 Results have been presented at the 2010 International Conference on Alzheimer's Disease.
    • 21 Apr 2008 Status change from recruiting to completed, according to clinicaltrials.gov.
    • 24 Jan 2008 The expected completion date for this trial is now 1 Mar 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top